Cediranib: a VEGF Receptor Tyrosine Kinase Inhibitor

• Asahara T , MuroharaT, SullivanAet al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964–967 (1997).
   PubMed Web of Science ®Google Scholar
• Gille H , KowalskiJ, LiBet al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): a reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276(5), 3222–3230 (2001).
   PubMed Web of Science ®Google Scholar
• Drevs J , SiegertP, MedingerMet al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(21), 3045–3054 (2007).
   PubMed Web of Science ®Google Scholar
• Hurwitz H , FehrenbacherL, NovotnyWet al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson DH , FehrenbacherL, NovotnyWet al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 22(11), 2184–2191 (2004).
   PubMed Web of Science ®Google Scholar
• Escudier B . Sorafenib for the management of advanced renal cell carcinoma.Expert Rev. Anticancer Ther.11(6), 825–836 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , MichaelsonMD, RedmanBGet al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Langer CJ , NataleRB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.Semin. Oncol.32(6 Suppl. 10), S23–S29 (2005).
   PubMed Web of Science ®Google Scholar
• Achen MG , StackerSA. Molecular control of lymphatic metastasis.Ann. NY Acad. Sci.1131, 225–234 (2008).
   PubMed Web of Science ®Google Scholar
• Gomez-Rivera F , Santillan-GomezAA, YounesMNet al. The tyrosine kinase inhibitor, AZD 2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res. 13(15 Pt 1), 4519–4527 (2007).
   PubMed Web of Science ®Google Scholar
• Goss G , ShepherdFA, LaurieSet al. A Phase I and pharmacokinetic study of daily oral cediranib, and inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer 45(5), 782–788 (2009).
   PubMed Web of Science ®Google Scholar
• Wedge SR , KendrewJ, HennequinLFet al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389–4400 (2005).
   PubMed Web of Science ®Google Scholar
• Mitchell CL , O’ConnorJP, RobertsCet al. A two-part Phase II study of cediranib in patients with advanced solid tumors: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother. Pharmacol. 68(3), 631–641 (2011).
   PubMed Web of Science ®Google Scholar
• Jain RK , DudaDG, ClarkJW, LoefflerJS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer.Nat. Clin. Pract. Oncol.3(1), 24–40 (2006).
   PubMedGoogle Scholar
• Batchelor TT , DudaDG, di TomasoEet al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817–2823 (2010).
   PubMed Web of Science ®Google Scholar
• Robinson ES , MatulonisUA, IvyPet al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin. J. Am. Soc. Nephrol. 5(3), 477–483 (2010).
   PubMed Web of Science ®Google Scholar
• Batchelor TT , MulhollandP, NeynsBet al. The efficacy of cediranib as monotherapy and in combination with lomustine compared with lomustine alone in patients with recurrent glioblastoma: a Phase III randomized study. Presented at: Proceedings of the 2010 Society for Neuro-Oncology Annual Meeting Montréal, Canada, 18–21 November 2010.
   Google Scholar
• Matulonis UA , BerlinS, IvyPet al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601–5606 (2009).
   PubMed Web of Science ®Google Scholar
• Hirte HW , VidalL, FlemingGFet al. A Phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. Presented at: Proceedings of the 44th ASCO Annual Meeting Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Raja FA , GriffinCL, QianWet al. Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br. J. Cancer 105(7), 884–889 (2011).
   PubMed Web of Science ®Google Scholar
• Cunningham D , WongRP, D’haensGet al. A Phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): final PFS results. Presented at: Proceedings of the 44th ASCO Annual Meeting Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Hoff PM , HochhausA, PestalozziBet al. Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (MCRC): a randomized, double-blind, Phase III study (HORIZON II). Presented at: Proceedings of the 35th ESMO Congress. Milan, Italy, 8–12 October 2010.
   Google Scholar
• Schmoll H , CunninghamD, SobreroAet al. mFOLFOX6 + cediranib vs. mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): a randomized, double-blind, Phase II/III study (HORIZON III). Presented at: Proceedings of the 35th ESMO Congress. Milan, Italy, 8–12 October 2010.
   Google Scholar
• Robertson JD , BotwoodNA, RothenbergML, SchmollHJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III.Clin. Colorectal Cancer8(1), 59–60 (2009).
   PubMed Web of Science ®Google Scholar
• Goss GD , ArnoldA, ShepherdFAet al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J. Clin. Oncol. 28(1), 49–55 (2010).
   PubMed Web of Science ®Google Scholar
• Ramalingam SS , BelaniCP, MackPCet al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097). J. Thorac. Oncol. 5(8), 1279–1284 (2010).
   PubMed Web of Science ®Google Scholar
• Gardner K , JudsonI, LeahyMet al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. Presented at: Proceedings of the 45th ASCO Annual Meeting. Orlando, FL, USA, 29 May–2 June 2009.
   Google Scholar
• Kummar S , StrassbergerA, MonksSPet al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). Presented at: Proceedings of the 47th ASCO Annual Meeting. Chicago, IL, USA, 3–4 June 2011.
   Google Scholar
• Sridhar SS , MackenzieSJ, HotteSDet al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A Phase II trial of the PMH Consortium. Presented at: Proceedings of the 44th ASCO Annual Meeting Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Mulders P , HawkinsR, NathanPet al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised Phase II study. Eur. J. Cancer 48(4), 527–537 (2012).
   PubMed Web of Science ®Google Scholar
• Yin JJ , ZhangL, MunasingueJ, LinnoilaRI, KellyK. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.Cancer Res.70(21), 8662–8673 (2010).
   PubMed Web of Science ®Google Scholar
• Najy AJ , JungYS, WonJJet al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate doi: 10.1002/pros.22481 (2011) (Epub ahead of print).
   Google Scholar

Websites

• ClinicalTrials.gov. http://clinicaltrials.gov/
   Google Scholar
• Sunitinib or Cediranib for Alveolar Soft Part Sarcoma. http://clinicaltrials.gov/ct2/show/NCT01391962
   Google Scholar